<DOC>
	<DOCNO>NCT02843789</DOCNO>
	<brief_summary>The aim study analyze variation adiponectinemia molecular form RA patient receive tocilizumab therapy .</brief_summary>
	<brief_title>Evolution Adipokines Body Composition Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy</brief_title>
	<detailed_description>Rheumatoid arthritis ( RA ) chronic inflammatory disease associate cardiovascular morbidity . Tocilizumab ( TCZ ) , monoclonal antibody interleukin-6 receptor effective new biotherapy treatment RA . This treatment associate increase LDL HDL-cholesterol lipid parameter . Adipokines adipose tissue-specific secreted molecule , many function regulation appetite , blood glucose immune response . Among adipokines , adiponectin exerts beneficial effect cardiovascular system . Patients RA also exhibit body composition change , include increase abdominal visceral fat . The impact tocilizumab therapy RA patient adipokines body composition know . This project aim explore evolution circulate adiponectin adipokines tocilizumab therapy RA . Body composition variation tocilizumab therapy also analyze .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Patients diagnosis RA require Tocilizumab therapy Subject provide write informed consent Corticosteroid therapy ( 10 mg/day prednisone equivalent ) Pregnant lactate woman Uncontrolled type 1 type 2 diabetes Uncontrolled dyslipidemia Elevated transaminase ( &gt; three time higher normal range ) History diverticulitis intestinal perforation Tocilizumab contraindication : Severe active infection , Hypersensitivity active substance excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Adipokines</keyword>
	<keyword>Tocilizumab</keyword>
</DOC>